Key result
Dabigatran showed a higher risk of myocardial infarction versus warfarin but similar rates versus placebo, suggesting warfarin has a more protective effect.
Why the study?
Does dabigatran increase the risk of myocardial infarction compared to warfarin, enoxaparin, or placebo in patients across multiple indications?
Meta-Analysis (n=42,484)
Does dabigatran increase the risk of myocardial infarction compared to warfarin, enoxaparin, or placebo in patients across multiple indications?
While dabigatran is associated with a higher rate of myocardial infarction compared to well-controlled warfarin, it maintains a positive overall benefit-risk ratio for major cardiovascular composite endpoints.
Answers are grounded in this paper and cite their sources.
Warrants MI risk caution with dabigatran versus warfarin; confirms differential anticoagulant effects in Level 1 evidence.
BACKGROUND: Dabigatran 150 mg twice daily was shown to be superior to warfarin in preventing stroke in subjects with nonvalvular atrial fibrillation (SPAF) in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapY) trial. Numerically, more myocardial infarctions occurred in patients receiving dabigatran compared with well-controlled warfarin. This observation prompted a comprehensive analysis of cardiovascular outcomes, including myocardial infarction, in all completed Phase II and III trials of dabigatran etexilate. METHODS: The analysis included comparisons of dabigatran with warfarin, enoxaparin, and placebo. Data were analyzed for the occurrence of cardiovascular events from 14 comparative trials (n = 42,484) in five different indications. Individual study data were evaluated, as well as pooled subject-level data grouped by comparator. RESULTS: In the pooled analysis of individual patient data comparing dabigatran with warfarin (SPAF and venous thromboembolism treatment indications), myocardial infarction occurrence favored warfarin (odds ratio [OR] 1.30, 95% confidence interval [CI] 0.96-1.76 for dabigatran 110 mg twice daily and OR 1.42, 95% CI 1.07-1.88 for dabigatran 150 mg twice daily). The clinically relevant composite endpoint of myocardial infarction, total stroke, and vascular death demonstrated numerically fewer events in dabigatran 150 mg patients (OR 0.87, 95% CI 0.77-1.00), but was similar for dabigatran 110 mg (OR 0.99, 95% CI 0.87-1.13). Dabigatran had similar myocardial infarction rates when compared with enoxaparin or placebo. CONCLUSION: These analyses suggest a more protective effect of well-controlled warfarin, but not enoxaparin, compared with dabigatran in preventing myocardial infarction in multiple clinical settings. Dabigatran showed an overall positive benefit-risk ratio for multiple clinically important cardiovascular composite endpoints in all evaluated clinical indications. In conclusion, these data suggest that myocardial infarction is not an adverse drug reaction associated with use of dabigatran.
No takes yet. Share an insight, caveat, or question.
Clemens et al. (2013) conducted a meta-analysis in Nonvalvular atrial fibrillation, venous thromboembolism, and other indications (n=42,484). Dabigatran vs. Warfarin, enoxaparin, or placebo was evaluated on Myocardial infarction (dabigatran 150 mg twice daily vs warfarin) (OR 1.42, 95% CI 1.07-1.88). Dabigatran showed a higher risk of myocardial infarction versus warfarin but similar rates versus placebo, suggesting warfarin has a more protective effect.
Synapse has enriched 10 related papers. Consider them for comparative context: